TY - JOUR
T1 - Congenital hyperreninemic hypoaldosteronism
T2 - A case report
AU - Yupanqui, Maria Elvira
AU - Schrader-Florez, Camila
AU - López-Ramírez, Sofía
AU - Valenzuela-Vallejo, Laura
AU - Perez-Barreto, Andrés
AU - Céspedes Salazar, Camila
AU - Forero Ronderos, Catalina
AU - Durán Ventura, Paola
N1 - Publisher Copyright:
© The Author(s) 2023.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Congenital hypoaldosteronism is a rare autosomal recessive or dominant endocrinopathy with variable penetrance, secondary to primary defects in aldosterone synthesis that could lead to hypovolemia, hyponatremia, hyperkalemia, failure to thrive, microcephaly, seizures, neurodevelopmental delay, or hearing loss. We present the case of a Colombian patient with congenital hypoaldosteronism, who owns two variants in the CPY11B2 gene, and a heterozygous pathogenic variant for nonclassical congenital adrenal hyperplasia. However, the patient missed follow-up and treatment for 6 years. At the age of 7 years, he resumed medical follow-up with laboratory findings of hyperreninemia and hypoaldosteronism, as well as clinical findings of strabismus, left mixed hyperacusis, and pathological short stature (−4.3 SD). Therefore, a trial of fludrocortisone therapy was started with subsequent improvement in renin levels, weight gain, and growth velocity. After 10 months of the start of the medication, he presented hypertension. There is no literature about the late treatment of this condition for pathological short stature.
AB - Congenital hypoaldosteronism is a rare autosomal recessive or dominant endocrinopathy with variable penetrance, secondary to primary defects in aldosterone synthesis that could lead to hypovolemia, hyponatremia, hyperkalemia, failure to thrive, microcephaly, seizures, neurodevelopmental delay, or hearing loss. We present the case of a Colombian patient with congenital hypoaldosteronism, who owns two variants in the CPY11B2 gene, and a heterozygous pathogenic variant for nonclassical congenital adrenal hyperplasia. However, the patient missed follow-up and treatment for 6 years. At the age of 7 years, he resumed medical follow-up with laboratory findings of hyperreninemia and hypoaldosteronism, as well as clinical findings of strabismus, left mixed hyperacusis, and pathological short stature (−4.3 SD). Therefore, a trial of fludrocortisone therapy was started with subsequent improvement in renin levels, weight gain, and growth velocity. After 10 months of the start of the medication, he presented hypertension. There is no literature about the late treatment of this condition for pathological short stature.
KW - CYP11B2
KW - fludrocortisone
KW - Growth
KW - hyperreninemic
KW - hypoaldosteronism
UR - http://www.scopus.com/inward/record.url?scp=85173674775&partnerID=8YFLogxK
U2 - 10.1177/2050313X231201724
DO - 10.1177/2050313X231201724
M3 - Article
AN - SCOPUS:85173674775
SN - 2050-313X
VL - 11
JO - SAGE Open Medical Case Reports
JF - SAGE Open Medical Case Reports
ER -